RGBP — Regen BioPharma Income Statement
0.000.00%
Last trade - 00:00
- $2.93m
- $3.37m
- $0.24m
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.11 | 0.11 | 0.171 | 0.236 | 0.237 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.806 | 0.319 | 1.15 | 0.67 | 0.922 |
Operating Profit | -0.696 | -0.209 | -0.976 | -0.435 | -0.686 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.62 | 3.41 | -6.77 | 2.44 | 1.16 |
Net Income After Taxes | -2.62 | 3.41 | -6.77 | 2.44 | 1.16 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2.62 | 3.41 | -6.77 | 2.44 | 1.16 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.62 | 2.73 | -6.77 | 2.44 | 1.02 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.93 | 2.89 | -2.97 | 0.805 | 0.289 |